We found an enhanced IFN signalling in breast cancer patients with mtp53, including an increased expression of IFNλ2, type III IFN, and IFNβ, type I IFN, as well as interferon-sensitive genes (ISGs) downstream of IFN (Fig. 1b). Here, IFNL2 is linked to breast carcinoma.